Oncotype DX maker Genomic Health announced last week that two studies recently presented at an international oncology conference could lead to the development of new predictive tests to help determine which patients are likely to respond to the targeted colon cancer drug Erbitux and the breast cancer chemotherapy Taxotere.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.